We are live on ! Find out more
CPX

Canaan Partners XI Portfolio holdings

AUM $127M
1-Year Est. Return 217.49%
This Fund
S&P 500
This Quarter Est. Return
-15.59%
1 Year Est. Return
+217.49%
3 Year Est. Return
+1,311.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
-$27.2M
Cap. Flow
-$741K
Cap. Flow %
-0.65%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$741K

Sector Composition

Rank Sector Weight
1 Healthcare 86.16%
2 Technology 12.4%
3 Financials 1.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYRA icon
1
Tyra Biosciences
TYRA
$1.91B
$60.7M 53.26%
4,409,991
– –
DAWN
2
DELISTED
Day One Biopharmaceuticals
DAWN
$30.6M 26.81%
2,491,561
-56,842
-2% -$741K
AEVA
3
Aeva Technologies
AEVA
$1.26B
$14.1M 12.4%
3,697,039
– –
RLYB icon
4
Rallybio
RLYB
$84.6M
$6.94M 6.09%
257,464
– –
ML
5
DELISTED
MoneyLion Inc.
ML
$1.64M 1.43%
75,581
– –

Similar funds

CF
Concorde Financial Dallas, Texas $127M AUM 24.97% 1-Year Est. Return
MF
Midwestern Financial Iowa City, Iowa $127M AUM 13.96% 1-Year Est. Return
SAP
Strategic Advisory Partners Greensboro, North Carolina $127M AUM
S
Storgate Dallas, Texas $127M AUM
PIP
PB Investment Partners Burlingame, California $127M AUM 0.83% 1-Year Est. Return
VDC
Van Diest Capital Poly City, Iowa $127M AUM
SIM
Summitas Investment Management Mckinney, Texas $128M AUM
PC
Pelham Capital London, United Kingdom $128M AUM 34.73% 1-Year Est. Return

Canaan Partners XI's Q3 2023 Portfolio in Review

As of Q3 2023, Canaan Partners XI held 5 positions worth $114M, down 19% from $141M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2023: portfolio turnover was 0%. Canaan Partners XI opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 83% a quarter earlier, followed by Technology and Financials.

  • Canaan Partners XI's biggest Q3 2023 reduction was Day One Biopharmaceuticals, cutting an estimated $741K.
  • Canaan Partners XI's ten largest holdings make up 100% of its $114M portfolio in Q3 2023.
  • Canaan Partners XI opened 0 new positions and closed 0 in Q3 2023.
  • Canaan Partners XI's portfolio value fell 19% quarter-over-quarter to $114M.

Based on Canaan Partners XI's 13F filing for Q3 2023, filed 11 Oct 2023.